HNSBF News and Press, Hansa Biopharma AB From 01/12/20

LUND, Sweden , Jan. 13, 2020 /PRNewswire/ --  Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019.  ...

LUND, Sweden , Dec. 13, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the outcome of a November 20th meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory path forward for...

Hansa Biopharma AB ( OTC:HNSBF ): Q3 GAAP EPS of -SEK2.36. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...

MALMÖ, Sweden , Oct. 31, 2019 /PRNewswire/ -- - Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation's (ESOT) ...

LUND, Sweden , Oct. 11, 2019 /PRNewswire/ -- Hansa Biopharma will publish its interim report for the first nine months of 2019 at 8:00 a.m. CET on October 31, 2019 . All interested parties are invited to participate in a telephone conference, which will include a presentation of the in...

LUND, Sweden , Sept. 25, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced that a date for a follow- up meeting with the U.S. Food and Drug Administration (FDA) has now been confirmed. The meeting will ta...

LUND, Sweden , Sept. 18, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced that positive imlifidase data were highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantation...

LUND, Sweden , Aug. 30, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that new imlifidase data will be highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantat...

LUND, Sweden , Aug. 21, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences: The Goldman Sachs Ninth Ann...

Hansa Biopharma AB ( OTC:HNSBF ): Q2 GAAP EPS of -SEK2.06. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...